Evidence map›Paper›PMID 33632320›Full record

ArticleMolecular autism2021

Increased aperiodic gamma power in young boys with Fragile X Syndrome is associated with better language ability.

Carol L Wilkinson, Charles A Nelson

Open access · goldAbstract read
In one paragraph

Article in Molecular autism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Behavioral Phenotype Associations With Resting State EEG Signal Complexity and Power Spectral Density in Fragile X Syndrome.Autism research : official journal of the International Society for Autism Research · 2026
    Article
  14. Article
  15. Alpha oscillations are dysrhythmic in Fragile X syndrome.bioRxiv : the preprint server for biology · 2026
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Carol L WilkinsonDivision of Developmental Medicine, Boston Children's Hospital, 1 Autumn Street, 6th Floor, Boston, MA, 02115, USA. Carol.wilkinson@childrens.harvard.edu.ORCID 0000-0002-4694-8564
Charles A NelsonDivision of Developmental Medicine, Boston Children's Hospital, 1 Autumn Street, 6th Floor, Boston, MA, 02115, USA.
Boston Children's Hospital · US

Funding

Neurobehavioral Research on Infants at Risk for SLI and AutismR01DC010290 · NIDCD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI NELSON, CHARLES ALEXANDER, TAGER-FLUSBERG, HELEN · 2009 to 2020
$7.5M
Translational Post-doctoral Training in NeurodevelopmentT32MH112510 · NIMH · BOSTON CHILDREN'S HOSPITAL · PI DAVID C GLAHN, CHARLES Alexander NELSON · 2017 to 2026
$2.6M
Neural Markers of Language Development in Fragile X Syndrome and Autism Spectrum DisorderK23DC017983 · NIDCD · BOSTON CHILDREN'S HOSPITAL · PI WILKINSON, CAROL LEE · 2020 to 2024
$859k
NIDCD NIH HHS K23 DC017983NIDCD NIH HHS R01 DC010290NIMH NIH HHS T32 MH112510
6 · The paper itself

Abstract

backgroundThe lack of robust and reliable clinical biomarkers in Fragile X Syndrome (FXS), the most common inherited form of intellectual disability, has limited the successful translation of bench-to-bedside therapeutics. While numerous drugs have shown promise in reversing synaptic and behavioral phenotypes in mouse models of FXS, none have demonstrated clinical efficacy in humans. Electroencephalographic (EEG) measures have been identified as candidate biomarkers as EEG recordings of both adults with FXS and mouse models of FXS consistently exhibit alterations in resting state and task-related activity. However, the developmental timing of these EEG differences is not known as thus far EEG studies have not focused on young children with FXS. Further, understanding how EEG differences are associated with core symptoms of FXS is crucial to successful use of EEG as a biomarker, and may improve our understanding of the disorder.

methodsResting-state EEG was collected from FXS boys with full mutation of Fmr1 (2.5-7 years old, n = 11) and compared with both age-matched (n = 12) and cognitive-matched (n = 12) typically developing boys. Power spectra (including aperiodic and periodic components) were compared using non-parametric cluster-based permutation testing. Associations between 30 and 50 Hz gamma power and cognitive, language, and behavioral measures were evaluated using Pearson correlation and linear regression with age as a covariate.

resultsFXS participants showed increased power in the beta/gamma range (~ 25-50 Hz) across multiple brain regions. Both a reduction in the aperiodic (1/f) slope and increase in beta/gamma periodic activity contributed to the significant increase in high-frequency power. Increased gamma power, driven by the aperiodic component, was associated with better language ability in the FXS group. No association was observed between gamma power and parent report measures of behavioral challenges, sensory hypersensitivities, or adaptive behaviors. LIMITATIONS: The study sample size was small, although comparable to other human studies in rare-genetic disorders. Findings are also limited to males in the age range studied.

conclusionsResting-state EEG measures from this study in young boys with FXS identified similar increases in gamma power previously reported in adults and mouse models. The observed positive association between resting state aperiodic gamma power and language development supports hypotheses that alterations in some EEG measures may reflect ongoing compensatory mechanisms.

Indexed as

Child LanguageBrainChildChild, PreschoolElectroencephalographyFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansMaleFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1BiomarkerE:I ratioElectroencephalographyFragile X SyndromeGammaLanguageOutcome measures

Identifiers

PMID33632320
PMCPMC7908768
OpenAlexW3132150262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.